在非洲地区减少B族链球菌疾病的挑战
本文综述了在非洲资源有限地区减少B族链球菌(GBS)疾病负担的证据与挑战。文章指出GBS是高收入国家新生儿败血症和脑膜炎的主要病因,而资源有限国家GBS疾病负担也较高,但产时抗生素预防(IAP)在撒哈拉以南非洲多数国家实施困难,GBS疫苗尚在研发中。综述探讨了非洲环境下减少侵袭性GBS疾病的策略、疫苗开发及预防措施的实际可行性。
要点
- GBS是新生儿败血症和脑膜炎的重要病因,资源有限国家疾病负担也较高。
- IAP在欧洲和北美显著减少早发型GBS疾病,但在撒哈拉以南非洲实施困难。
- GBS疫苗尚在研发中,接近III期试验,但尚未可用。
核心结论
- 在非洲资源有限地区减少侵袭性GBS疾病面临挑战,需要探索适合当地实际的预防策略。
研究设计与样本
- 本文为综述,探讨非洲环境下减少侵袭性GBS疾病的策略、GBS疫苗开发及预防措施的实际可行性。
主要发现
- GBS是高收入国家新生儿败血症和脑膜炎的主要病因,与高新生儿死亡率和发病率相关。
- 越来越多证据提示资源有限国家GBS疾病负担高。
- 在欧洲和北美,IAP已使早发型GBS疾病大幅减少。
- 识别应接受IAP的孕妇的方法及减少晚发型GBS疾病的方法存在争议,且在多数撒哈拉以南非洲国家具有挑战性。
- GBS疫苗正接近III期试验,但仍处于开发阶段。
临床怎么用
- 在非洲资源有限地区,需根据当地条件评估和实施GBS疾病预防策略,IAP的推广面临实际挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Group B Streptococcus (GBS) is a leading cause of neonatal sepsis and meningitis in high-income settings and is associated with high rates of neonatal mortality and morbidity. There is now increasing evidence to suggest that there is a high GBS disease burden in resource-limited countries, and it is therefore critically important to identify suitable and practical preventive strategies. In Europe and North America, intrapartum antibiotic prophylaxis (IAP) has led to a dramatic reduction of early-onset GBS disease. However, the methods for identifying pregnant women who should receive IAP and how to reduce late-onset GBS disease are not without controversy and are challenging for most sub-Saharan African countries. GBS vaccines are approaching phase III trials but are still under development. This review aims to explore the current evidence related to strategies for reducing invasive GBS disease in an African setting, the development of a GBS vaccine and whether preventative measures against GBS disease can be practically implemented.
引用
- Nishihara Y, Dangor Z, French N, et al. Challenges in reducing group B Streptococcus disease in African settings. Arch Dis Child. 2016. PMID: 27831912. doi:10.1136/archdischild-2016-311419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。